|Bid||4.0000 x 2200|
|Ask||4.8700 x 1000|
|Day's range||4.4200 - 4.5450|
|52-week range||3.0100 - 7.1900|
|Beta (5Y monthly)||1.26|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
The consensus price target hints at a 78.9% upside potential for GENFIT S.A. Unsponsored ADR (GNFT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
The mean of analysts' price targets for GENFIT S.A. Unsponsored ADR (GNFT) points to a 59.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
What happened Shares of Genfit (NASDAQ: GNFT) were skyrocketing 25% higher at 11:58 a.m. EST on Wednesday. The big jump came after the company announced positive results from a phase 2 study evaluating elafibranor in treating primary biliary cholangitis (PBC), an autoimmune disease that causes scarring of bile ducts in the liver.